This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Development of Oral Nalbuphine Dosage Form (NAL)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2009 by Tri-Service General Hospital.
Recruitment status was:  Recruiting
Information provided by:
Tri-Service General Hospital Identifier:
First received: June 17, 2009
Last updated: June 18, 2009
Last verified: June 2009
The purpose of this study is to investigate possible responses to pharmacokinetic properties for nalbuphine oral formulations in healthy volunteers.

Condition Intervention
Healthy Drug: nalbuphine

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Pharmacokinetic Study of Oral Nalbuphine in Normal Healthy Subjects

Resource links provided by NLM:

Further study details as provided by Tri-Service General Hospital:

Primary Outcome Measures:
  • Pharmacokinetic parameter eq Cmax, AUC, Cl, T1/2 [ Time Frame: 24 hours ]

Estimated Enrollment: 60
Study Start Date: September 2008
Estimated Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: nalbuphine Drug: nalbuphine
oral dosage form, 66 mg, single dose


Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Normal healthy adult subjects between 20-40 years of age.
  • Body weight within 80-120% of ideal body weight. Ideal body weight = (height-80)0.7
  • Acceptable medical history and physical examination including:

    • Normal chest X-ray and ECG results within six months prior to Period I dosing.
    • No particular clinical significance in general disease history within two months prior to Period I dosing.
  • Acceptable clinical laboratory determinations without significant deviation from normal values within two months prior to Period I dosing, which includes:

    • AST (SGOT)
    • ALT (SGPT)
    • Gama-GT
    • alkaline phosphatase
    • total bilirubin
    • albumin
    • glucose
    • BUN
    • uric acid
    • creatinine
    • total cholesterol
    • triglyceride(TG)
  • Acceptable hematology within two months prior to the study, which includes hemoglobin, hematocrit, red blood cells, MCV, MCH, MCHC, white blood cells, differential white blood cells and platelets.
  • Acceptable urinalysis within two months prior to the study, which includes pH, blood, glucose and protein.
  • Signed the written informed consent to participate in this study.

Exclusion Criteria:

  • Recent history of drug or alcohol addiction or abuse.
  • A clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease (as determined by the clinical investigator).
  • History of allergic response(s) to nalbuphine or related drugs.
  • History of clinically significant allergies including drug allergies or allergic bronchial asthma.
  • Evidence of chronic or acute infectious diseases.
  • Any clinically significant illness or surgery during the four weeks prior to Period I dosing (as determined by the clinical investigator).
  • Taking any drug known to induce or inhibit hepatic drug metabolism within one month prior to the beginning of the study.
  • Receiving any investigational drug within one month prior to Period I dosing.
  • Taking any prescription medication or any nonprescription medication within two weeks prior to Period I doing.
  • Donating greater than 150 ml of blood within two months prior to Period I dosing or donating plasma (e.g., plasmapheresis) within 14 days prior to Period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study.
  • Consumption of caffeine, xanthine-containing products (i.e., coffee, tea, caffeine-containing sodas, colas and chocolate, etc.) and/or alcohol at least 48 hours prior to days on which dosing is scheduled and during the periods when blood samples are being collected.
  • Any other medical reason as determined by the clinical investigator.
  • Patient is pregnant or breastfeeding. Women of childbearing potential must have a negative urine pregnancy test at Baseline.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00924079

Tri-Service General Hospitial Recruiting
Taipei, Taiwan, 11490
Contact: Ho Shung-Tai, MD    886-2-87927125   
Principal Investigator: Ho Shung-Tai, MD         
Sponsors and Collaborators
Tri-Service General Hospital
  More Information

Responsible Party: Ho Shung-Tai/Professor of the department of anesthsiology, Department of anesthsiology of Tri-service General Hospitial Identifier: NCT00924079     History of Changes
Other Study ID Numbers: NAL001
Study First Received: June 17, 2009
Last Updated: June 18, 2009

Keywords provided by Tri-Service General Hospital:
Analysis of plasma concentration of nalbuphine

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists processed this record on August 18, 2017